Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/7/2025

Management of Asperger's Syndrome with Sleep Difficulty, Anxiety, Depression, and Restless Leg Syndrome

Restless Leg Syndrome Management

  • The American Academy of Sleep Medicine recommends gabapentin as first-line therapy for RLS with moderate certainty of evidence, starting with 300 mg at bedtime and titrating to 300 mg three times daily (900 mg/day total) 1, 3
  • Supplement with iron if ferritin ≤75 ng/mL or transferrin saturation <20%, using oral ferrous sulfate as first-line iron supplementation, or IV ferric carboxymaltose if oral therapy fails 1, 2
  • Eliminate or reduce alcohol, caffeine, and nicotine, especially within 3 hours of bedtime, and review all current medications for RLS-exacerbating agents including antihistamines, antipsychotics, and other serotonergic medications 1, 2

Sleep Difficulty Management in Autism Spectrum Disorder

  • Implement educational/behavioral approaches as first-line treatment for insomnia in ASD patients, including consistent bedtime routines with visual schedules and addressing core behavioral deficits 4
  • Melatonin is the most effective evidence-based treatment for sleep latency and total sleep time in ASD patients, decreasing sleep latency and increasing total sleep time by approximately 1.79-1.91 hours in controlled trials 6

Depression and Anxiety Management

  • Bupropion may be the preferred antidepressant as it may actually reduce RLS symptoms rather than worsen them, while avoiding SSRIs and SNRIs that can worsen RLS 1
  • Consider mirtazapine if sleep remains problematic, though monitor for increased periodic limb movements 6

Ongoing Monitoring and Critical Pitfalls to Avoid

  • Reassess iron studies every 6-12 months and continue supplementation as needed, and monitor for gabapentin side effects and adjust dose based on response 1
  • Do not start venlafaxine without first addressing RLS, and do not use dopamine agonists for RLS due to high risk of augmentation (paradoxical worsening of symptoms) 1